

1 **Pre-clinical evaluation of antiviral activity of nitazoxanide against Sars-CoV-2**

2 Jean-Sélim Driouich¹, Maxime Cochin¹, Franck Touret¹, Paul-Rémi Petit¹, Magali Gilles¹, Grégory
3 Moureau¹, Karine Barthélémy¹, Caroline Laprie², Thanaporn Wattanakul³, Palang Chotsiri³, Richard M.
4 Hoglund^{3,4}, Joel Tarning^{3,4}, Fanny Escudié⁵, Ivan Scandale⁵, Eric Chatelain⁵, Xavier de Lamballerie¹,
5 Caroline Solas^{1,6}, Antoine Nougairède¹

6

7 ¹ Unité des Virus Émergents (UVE: Aix-Marseille University -IRD 190-Inserm 1207), Marseille, France.

8 ² Laboratoire Vet-Histo, Marseille, France

9 ³ Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University,
10 Bangkok, Thailand.

11 ⁴ Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine,
12 University of Oxford, Oxford, United Kingdom.

13 ⁵ Drugs for Neglected Diseases initiative, Geneva, Switzerland

14 ⁶ APHM, Laboratoire de Pharmacocinétique et Toxicologie, Hôpital La Timone, Marseille, France.

15

16

17

18 **Abstract**

19 To address the emergence of SARS-CoV-2, multiple clinical trials in humans were rapidly started,
20 including those involving an oral treatment by nitazoxanide, despite no or limited pre-clinical
21 evidence of antiviral efficacy. In this work, we present a complete pre-clinical evaluation of the
22 antiviral activity of nitazoxanide against SARS-CoV-2. First, we confirmed the *in vitro* efficacy of
23 nitazoxanide and tizoxanide (its active metabolite) against SARS-CoV-2. Then, we demonstrated
24 nitazoxanide activity in a reconstructed bronchial human airway epithelium model. In a SARS-CoV-2
25 virus challenge model in hamsters, oral and intranasal treatment with nitazoxanide failed to impair
26 viral replication in commonly affected organs. We hypothesized that this could be due to insufficient
27 diffusion of the drug into organs of interest. Indeed, our pharmacokinetic study confirmed that
28 concentrations of tizoxanide in organs of interest were always below the *in vitro* EC₅₀. These
29 preclinical results suggest, if directly applicable to humans, that the standard formulation and dosage
30 of nitazoxanide is not effective in providing antiviral therapy for Covid-19.

31

32 **Keywords**

33 COVID-19, SARS-CoV-2, antiviral therapy, pre-clinical research, nitazoxanide, animal model

34 Introduction

35 The threat of a global pandemic caused by a virus from the *Coronaviridae* family, which are
36 enveloped positive-stranded RNA viruses, has been hanging over the whole world since the
37 emergence of the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East
38 respiratory syndrome (MERS-CoV). In December 2019, cases of pneumonia were reported in Wuhan,
39 China, (1). Few months later, the causative agent was identified as a new betacoronavirus (2). Named
40 SARS-CoV-2, this pathogen progressed worldwide to such an extent that its disease, called
41 coronavirus disease 2019 (COVID-19), was characterized as a pandemic by the World Health
42 Organization on March 2020 (3). COVID-19 leads to a broad spectrum of clinical syndromes, ranging
43 from pauci-symptomatic disease to severe pneumonia and acute respiratory distress syndrome (4).
44 To date, there are no approved small molecules targeting coronavirus viral replication.. Therefore,
45 drug repurposing has been considered as an interesting strategy to find an active antiviral therapy
46 against SARS-CoV-2.

47
48 Nitazoxanide (NTZ) was originally developed as an antiprotozoal agent and marketed for the
49 treatment of *Giardia* and *Cryptosporidium* infections. In recent years, it was identified as a broad-
50 spectrum antiviral drug (5, 6). NTZ, and its active circulating metabolite, tizoxanide (TIZ), inhibit the
51 replication of a wide range of RNA and DNA viruses in cell culture assays including hepatitis B,
52 hepatitis C, rotavirus, norovirus, dengue, yellow fever, Japanese encephalitis virus and the human
53 immunodeficiency virus (6-8). Its inhibitory activity against viruses inducing respiratory infections was
54 specifically investigated (9). Notably, NTZ possesses *in vitro* antiviral activity against influenza virus by
55 blocking the maturation of the viral hemagglutinin, as well as against MERS coronavirus and other
56 coronaviruses by inhibiting expression of the viral N protein (8, 10-12).

57
58 It is thus quite naturally that this molecule was rapidly considered as a potential repurposing
59 candidate for COVID-19 management (13-18). NTZ was one of the first molecules studied *in vitro*
60 against SARS-CoV-2. One of the earliest studies on SARS-CoV-2 reported a 50% effective
61 concentration (EC₅₀) of 2.12µM in Vero E6 cells at 48 h post-infection (19). Assumptions regarding the
62 possible role of TIZ against numerous targets involved in SARS-CoV-2 pathogenesis affecting viral
63 entry and multiplication were rapidly proposed (20). Additionally, recent findings have also
64 demonstrated that NTZ could inhibit the TMEM16 protein, a calcium-activated ion channel involved
65 in phospholipid transposition between the cell membranes, and block SARS-CoV-2-Spike induced
66 syncytia (21). In addition, NTZ may have the capacity to boost host innate immune responses,
67 affecting the well-described COVID-19 inflammatory cytokine storm. Ambitious expectations have

68 also been raised about its potential ability to improve multi-organ damage and providing added value
69 to patients with comorbidities (20). Consequently, many clinical trials in human investigating the
70 efficacy and the safety of an oral treatment of NTZ alone or in combination with other anti-SARS-
71 CoV-2 candidates are ongoing worldwide (<https://clinicaltrials.gov/>; search terms: nitazoxanide |
72 Covid19).

73


74 However, a pre-clinical *in vivo* investigation of the activity of NTZ against SARS-CoV-2 had yet to be
75 conducted. In the present study, we first confirmed the antiviral efficacy of NTZ and TIZ *in vitro*
76 before investigating activity against SARS-CoV-2 using reconstituted human airway epithelium and a
77 previously described Syrian hamster model (22, 23). A population pharmacokinetic model was
78 developed to compare exposure in hamsters and humans, with the aim of assessing whether the
79 exposure to NTZ and TIZ in preclinical animal species can be achieved in humans, and whether the
80 antiviral potency observed *in vitro* can be recovered *in vivo*.

81 Results

82

83 *In vitro* efficacy of nitazoxanide (NTZ)

84 Using two different cell lines, the VeroE6 (ACE2⁺/TMPRSS2⁻) and Caco-2 cells (ACE2⁺/TMPRSS2⁺), we
 85 first evaluated the *in vitro* efficacy of nitazoxanide (NTZ) and tizoxanide (TIZ) against SARS-CoV-2.
 86 Anti-viral potency was assessed in a viral RNA yield reduction assay by qRT-PCR as previously
 87 described (23-25). In VeroE6 cells, NTZ and TIZ inhibited viral replication with EC₅₀'s of 3.19 and
 88 7.48 μM and EC₉₀'s of 10.27 and 9.27 μM, respectively, while both CC₅₀'s were above 60 μM (Figure 1).
 89 Selectivity Index (SI=CC₅₀/EC₅₀) were higher than 13.3 for both molecules. In Caco-2 cells, NTZ
 90 exhibited an EC₅₀ of 0.58 μM, an EC₉₀ of 1.75 μM and a CC₅₀ of 9.15 μM resulting in a SI of 15.8 (Figure
 91 1).



92

93 Figure 1: Antiviral activity of NTZ and TIZ in Vero E6 and Caco-2 cells.

94 Dose response curve and cell viability for: NTZ in Vero E6 (a) and Caco-2 (b) cells and for TIZ in Vero E6 cells (c). D: Table of
 95 EC₅₀, EC₉₀, CC₅₀. Results presented in the table for NTZ in VeroeE6 are the mean ± SD from three independent experiments.
 96 Graphical representation is from one representative experiment.


97

98

99 *Ex vivo* efficacy of NTZ

100 We then investigated the *ex vivo* efficacy of NTZ using a recently described model of reconstituted
 101 human airway epithelial of bronchial origin (26). Five different concentrations of NTZ (20; 10; 5; 2.5;

102 1.25 μ M) were tested in duplicate while Remdesivir, at an active concentration of 10 μ M, was used as
103 a positive control. The basolateral sides of the epithelia were exposed to the drugs from time of
104 infection until day 4 post infection (dpi). Media with fresh drug were renewed at 1,2 and 3 dpi. Viral
105 excretion was assessed at 2, 3 and 4 dpi, by measuring viral RNA yields and infectious titers at the
106 apical side of the epithelium using quantitative real time RT-PCR and TCID₅₀ assays, respectively. No
107 antiviral efficacy was detected when viral excretion was assessed by quantification of viral RNA
108 (Figure 2-A). However, at 3 and 4 dpi, a significant reduction of infectious titers was observed when
109 concentrations of NTZ above its EC₅₀ were used (with p values ranging from 0.01-0.05 for 5 μ M, 0.001-
110 0.01 for 10 μ M and 0.0001-0.001 for 20 μ M) (Figure 2).



111

112 Figure 2: Antiviral activity of NTZ in a bronchial human airway epithelium.

113 Kinetics of virus excretion at the apical side of the epithelium measured using an RT-qPCR assay (A) and a TCID₅₀ assay (B).
114 Data represent mean \pm SD. Statistical significance was calculated by 1-way ANOVA versus untreated group. Remdesivir at
115 10 μ M was used as a positive drug control. *, ** and *** indicate and average significant value lower than that of the
116 untreated group, with a p-value ranging between 0.01-0.05, 0.001-0.01 and 0.0001-0.001, respectively. Result are the mean
117 \pm SD of two independent experiment with in each experiment two independent inserts.

118

119

120 ***In vivo* efficacy of NTZ**

121 Considering these results, we further investigated the potential antiviral activity of NTZ *in vivo* using a
122 previously described hamster model of SARS-CoV-2 infection (22, 23, 27).

123

124 **Efficacy evaluation of a NTZ oral treatment**


125

126 In a first set of experiments, we explored the antiviral efficacy of a NTZ suspension (90% sterile
127 distilled water, 7% of tween 80 and 3% of ethanol 80%). During two independent experiments,
128 groups of 6 hamsters were intranasally infected with 10⁴ TCID₅₀ of SARS-CoV-2 and received NTZ
129 orally at doses of 500mg/kg/day BID or 750mg/kg/day TID (Figure 3a). Untreated groups of 6
130 hamsters received the suspension vehicle BID or TID. A group of 6 animals was treated with
131 favipiravir (FVP) intraperitoneally (926mg/kg/day BID) as positive control in one experiment (22).

132

133 Hamsters treated with 500mg/kg/day BID or 750mg/kg/day TID of NTZ for 3 days (0, 1 and 2dpi),
134 showed no significant differences for either infectious titers (measured using TCID₅₀ assay) or viral
135 RNA yields (measured using quantitative real time RT-PCR assay) in clarified lung homogenates at 3
136 dpi compared to untreated animals ($p \geq 0.0989$) (Figure 3b, 3c, 3f and 3g). No significant difference
137 was detected with regards to viral RNA yields in plasma at 3 dpi ($p \geq 0.4697$) (Figure 3d and 3h).
138 Administration of FVP, however, led as expected to significant reductions of both infectious titers
139 and viral RNA yields in clarified lung homogenates ($p \leq 0.0011$) (Figure 3b and 3c). NTZ-treated animals
140 showed clinical signs of illness/suffering, with their mean normalized weight becoming significantly
141 lower than that of untreated animals, at 3 dpi for animals treated with 500mg/kg/day BID and at 2
142 dpi for animals treated with 750mg/kg/day TID ($p = 0.0158$ and $p = 0.0314$ respectively) (Figure 3e and
143 3i).

144 In another independent experiment, we tried to assess the antiviral efficacy of a longer treatment
145 period. Despite receiving 500mg/kg/day of NTZ BID for 4 days (0, 1, 2 and 3 dpi), hamsters exhibited
146 no significant reduction at 5 dpi of either infectious titers ($p = 0.1775$) or viral RNA ($p = 0.7003$) yields in
147 their clarified lung homogenates, or viral RNA yields plasma ($p = 0.1305$) (Figure 3j, 3k and 3l).
148 However, they did not show any clinical signs of illness/suffering compared to untreated animals
149 (Figure 3m).



150


151 Figure 3: Antiviral activity of oral treatment of NTZ in a hamster model.

152 Groups of 6 hamsters were intranasally infected with 10^4 TCID₅₀ of virus. **a** Experimental timeline. **b, f, j** Viral replication in
 153 lung based on infectious titers (measured using a TCID₅₀ assay) expressed in TCID₅₀/g of lung (n=6 animals/group). **c, g, k**
 154 Viral replication in lung based on viral RNA yields (measured using an RT-qPCR assay) expressed in viral genome copies/g of
 155 lung (n=6 animals/group). **d, h, l** Plasma viral loads (measured using an RT-qPCR assay) are expressed in viral genome
 156 copies/mL of plasma (the dotted line indicates the detection threshold of the assay) (n=6 animals/group). **e, i, m** Clinical
 157 course of the disease (n=6 animals/group). Normalized weight at day n was calculated as follows: % of initial weight of the
 158 animal at day n. Data represent mean \pm SD (Details in Supplementary Data 1). *** and ** symbols indicate that the average
 159 value for the group is significantly lower than that of the untreated group with a p-value ranging between 0.0001-0.001 and
 160 0.001-0.01 respectively (Details in Supplementary Data 2).

161

162 We also explored the impact of NTZ treatment on lung pathological changes induced by SARS-CoV-2,
 163 in an independent experiment. Groups of 4 hamsters, intranasally infected with 10^4 TCID₅₀ of SARS-
 164 CoV-2, were orally treated at a dose of 500mg/kg/day BID for 4 days (0, 1, 2 and 3 dpi) (Figure 4a).
 165 Untreated hamsters (group of 4 animals) received the suspension vehicle BID. Animals were
 166 sacrificed at 5 dpi and a cumulative score from 0 to 10 (taking into account severity of inflammation,

167 alveolar hemorrhagic necrosis and vessel lesions) was calculated and then assigned to a grade of
168 severity (0=normal; 1=mild; 2=moderate; 3=marked and 4=severe; details in Supplementary Data 3
169 and 4). All animals, treated and untreated, displayed severe pulmonary impairments. Marked and
170 severe histopathological damages in lungs for both groups were identified resulting in no significant
171 difference of histopathological cumulative scores (Figure 4b). At 3 dpi, animals showed clinical signs
172 of illness/suffering, with their mean normalized weight becoming significantly lower than that of
173 untreated animals (Supplementary Fig. 1).



174

175 Figure 4: Lung histopathological changes.

176 Groups of 4 animals were intranasally infected with 10^4 TCID₅₀ of virus and sacrificed at 5 dpi. Based on severity of
 177 inflammation, alveolar hemorrhagic necrosis and vessel lesions, a cumulative score from 0 to 10 was calculated and
 178 assigned to a grade of severity (I, II, III and IV). **a** Experimental timeline. **b** Scoring of pathological changes (Details in
 179 Supplementary Data 3 and 4). **c** Representative images of bronchial inflammation (scale bar: 100 μ): severe peribronchiolar
 180 inflammation and bronchiole filled with numerous neutrophils, marked peribronchiolar inflammation and normal bronchi.

181 **d** Representative images of alveolar inflammation (scale bar: 100 μ): severe infiltration of alveolar walls, alveoli filled with
 182 neutrophils/macrophages, marked infiltration of alveolar walls, some alveoli filled with neutrophils/macrophages and
 183 normal alveoli. **e** Representative images of vessel inflammation (scale bar: 100 μ): moderate accumulation of inflammatory
 184 cells in arteriolar walls and normal arteriole.

185

186 To investigate if the lack of efficacy seen in lungs was due to an inadequate drug diffusion, we
 187 assessed the exposure and the lung distribution of TIZ (the active circulating metabolite of NTZ). We
 188 used tissues from infected animals sacrificed at 3 dpi following multiple administration (animals from
 189 Figure 3); an additional group of uninfected animals treated with a single dose of 13.5mg was used as
 190 control. TIZ concentration in plasma and in lung was quantified at 1, 2 and 4 hours post treatment for
 191 the single dose analysis (group of 3 animals) and at 12 hours after the last administration for the
 192 multiple dose analysis (group of 6 animals).

193 These animals exhibited low penetration rates of TIZ in lungs, resulting in lung/plasma ratio ranging
 194 from 2.2% to 4.8% after single-dose administration (Table 1). Lung concentrations of TIZ were below
 195 the TIZ EC₅₀ found *in vitro* with Vero E6 cells (7.48 μ M, i.e 1.98 μ g/mL), as well as effective NTZ
 196 concentrations *ex vivo* (5 μ M, i.e 1.54 μ g/mL), and were not quantifiable in a total of 5 out of 9
 197 animals (one at 1 hour, two at 2 hours and two at 4 hours) (Table 1). After 3 days of multiple dose
 198 treatment, TIZ trough concentrations (12 hours after the last administration) in lungs were still below
 199 the *in vitro* EC₅₀ and not quantifiable in a total of 8 out of 12 animals (four for each multiple dose
 200 concentration) (Table 1).

201

	Time post-treatment	Plasma μ g/mL	Lung μ g/g	L/p ratio (%)
Single Dose: 13.5mg (control uninfected)	1 hour	5.16 \pm 4.24 (19.4 \pm 16.0 μ M)	0.16 ; 0.22 \S (0.61 ; 0.84 μ M/g)	4.8 ; 2.2
	2 hours	3.39 \pm 1.76 12.8 \pm 6.62 μ M	0.13 \Re (0.50 μ M/g)	2.7
	4 hours	0.82 \pm 0.57 (3.10 \pm 2.16 μ M)	0.06 \Re (0.23 μ M/g)	4.2
Multiple Dose: 500mg/kg/day BID (at 3 dpi)	12 hours	0.94 \pm 1.07 \S (3.54 \pm 4.21 μ M)	0.06 ; 0.06 \S (0.21 ; 0.21 μ M/g)	2.7 ; 32.8
Multiple Dose: 750mg/kg/day TID (at 3 dpi)	12 hours	1.49 \pm 1.15 (5.63 \pm 4.35 μ M)	0.07 ; 0.16 \S (0.28 ; 0.60 μ M/g)	2.9 ; 6.3

202

203 Table 1: Plasma and lung concentrations of TIZ after administration of a single dose or multiple dose of NTZ.
 204 Multiple Dose: PK realized after 3 days of nitazoxanide administered two or three times a day, at the end of the dosing
 205 interval (trough concentrations). Data represent mean \pm SD for plasma concentrations and individual values for lung
 206 concentrations and L/p ratios. These data represent a summary of Supplementary Data 4. Symbols \S , \Re and $\$$ represent
 207 respectively 1, 2 and 4 values below the limit of quantification.


208

209 NTZ efficacy evaluation following intranasal administration

210

211 To assess other administration routes for NTZ, we explored the antiviral efficacy of an intranasal NTZ
 212 emulsion (aqueous phase: sterile distilled water 94% and absolute ethanol 6%; organic phase: NTZ

213 20mg/mL in cinnamaldehyde 75% and Kolliphore EL 25%). Hamsters were intranasally infected with
214 10^4 TCID₅₀ of SARS-CoV-2. A group of 6 hamsters received intranasally 2.8mg/kg/day TID of NTZ
215 (Figure 5a). An untreated group of 6 hamsters received the emulsion vehicle TID. All treatments were
216 started at the day of infection and ended at day 2 post infection. Viral replication was assessed in
217 lungs, plasma and nasal turbinates at 3 dpi.
218
219 NTZ intranasal treatment led to a significant increase of infectious titers in clarified lung
220 homogenates ($p=0.0003$) (Figure 5b). No significant differences were observed when looking at viral
221 RNA yields in both clarified lung homogenates and plasma with both intranasal treatments
222 ($p \geq 0.4530$) (Figure 5c and 5d). In nasal turbinates, no significant differences of infectious titers were
223 observed between the groups ($p=0.6295$) (Figure 5e). When looking at viral RNA yields, NTZ
224 treatment induced a significant reduction of viral RNA load in nasal turbinates ($p=0.0037$) (Figure 5f).
225 Animals treated with NTZ intranasally from 1 to 3 dpi, showed clinical signs of illness/suffering, with
226 their mean normalized weight becoming significantly lower than that of untreated animals
227 ($p=0.0314$) (Figure 5g).



228

229 Figure 5: Antiviral activity of intranasal treatment of NTZ in a hamster model.

230 Groups of 6 hamsters were intranasally infected with 10⁴ TCID₅₀ of virus. **a** Experimental timeline. **b** Viral replication in lung
 231 based on infectious titers (measured using a TCID₅₀ assay) expressed in TCID₅₀/g of lung (n=6 animals/group). **c** Viral
 232 replication in lung based on viral RNA yields (measured using an RT-qPCR assay) expressed in viral genome copies/g of lung
 233 (n=6 animals/group). **d** Plasma viral loads (measured using an RT-qPCR assay) are expressed in viral genome copies/mL of
 234 plasma (the dotted line indicates the detection threshold of the assay) (n=6 animals/group). **e** Viral replication in nasal
 235 turbinates based on infectious titers (measured using a TCID₅₀ assay) expressed in TCID₅₀/copy of β-actine gene (n=6
 236 animals/group). **f** Viral replication in nasal turbinates based on viral RNA yields (measured using an RT-qPCR assay)
 237 expressed in viral genome copies/copy of β-actine gene (n=6 animals/group). **g** Clinical course of the disease (n=6
 238 animals/group). Normalized weight at day n was calculated as follows: % of initial weight of the animal at day n. Data
 239 represent mean ± SD (Details in Supplementary Data 1). ** symbols indicate that the average value for the group is
 240 significantly lower than that of the untreated group with a p-value ranging between 0.001-0.01 (Details in Supplementary
 241 Data 1).

242

243 To confirm these results, the experiment was repeated independently. Overall, no significant
 244 differences in viral replication between treated and untreated hamsters were observed in either
 245 clarified lung homogenates, plasma or nasal turbinates (Supplementary Fig. 2). Once again, hamsters
 246 treated with NTZ intranasally from 1 to 3 dpi, showed clinical signs of illness/suffering, with their

247 mean normalized weight becoming significantly lower than that of untreated animals
248 (Supplementary Fig. 2).

249

250 Similarly to the oral administration study, and to investigate a potential issue regarding drug
251 distribution to the compartment of choice, we also assessed the plasma, lung and nasal turbinates
252 concentrations of TIZ following intranasal NTZ administration in infected animals treated by multiple
253 doses, 12 hours after the last administration (group of 6 hamsters from figure 5). Overall, TIZ was
254 detectable in only 2 out of 6 animals (one in plasma and lung ; one in lung and nasal turbinates)
255 (Supplementary Table 1) but TIZ concentrations were below the EC_{50} found *in vitro* and the active
256 concentration *ex vivo*.

257

258 Pharmacokinetic modelling

259

260 We characterized the pharmacokinetic profile of TIZ in hamster after administration of the same NTZ
261 suspension or TIZ formulated in 10% [Tween 80, 80% EtOH (70:30 v/v)] and 90% distilled water,
262 homogenous opaque suspension. Groups of 3 hamsters received an oral single dose of 485mg/kg,
263 98.1mg/kg or 25.5mg/kg of NTZ or 96.4mg/kg of TIZ. The corresponding concentration-time curves
264 for NTZ administration only are presented in Supplementary Fig. 3. Notably, similar concentration-
265 time curves of TIZ were observed following oral administration of 98.1 NTZ or 96.4mg/kg of TIZ,
266 suggesting full in-vivo conversion of NTZ into TIZ (Supplementary Fig. 3). The observed TIZ plasma
267 concentration-time data in hamster, following oral administration of NTZ and TIZ, were characterized
268 using nonlinear mixed-effects modelling. The data were best described by a two-compartment
269 disposition model with first-order absorption. The population pharmacokinetic parameters estimates
270 from the final model are presented in Supplementary Table 2. Time to maximum concentration (T_{max})
271 and terminal elimination half-life ($t_{1/2}$) were estimated to 0.276h and 0.80h, respectively. Graphically,
272 the model showed good adequacy between predicted concentrations and observed concentrations
273 (Supplementary Fig. 4)

274 Simulated secondary pharmacokinetic parameters (C_{max} and AUC_{0-24h}) at each NTZ dose derived from
275 the population pharmacokinetic model are presented in Table 2.

276

NTZ dose (mg/kg)	C_{max} ($\mu\text{g}/\text{ml}$)	AUC_{0-24h} ($\mu\text{g}\cdot\text{h}/\text{ml}$)
25.0	3.14	4.18
50.0	6.27	8.36
100	12.5	16.7
125	15.7	20.9
250	31.4	41.8
500	62.7	83.6

277


278 Table 2: Simulated pharmacokinetic parameters derived from nonlinear mixed-effect modelling using population mean
279 values and median body weight of 0.126kg. C_{max} : maximum plasma drug concentration; AUC_{0-24h} : area under the
280 concentration-time curve from time 0 to 24h.

281

282

283 We then compared the pharmacokinetic profile of TIZ in hamster to that in human. The
284 pharmacokinetic model developed to describe the TIZ concentration-time data in hamster was used
285 to simulate plasma drug exposures in hamster using different dose regimens. From these
286 simulations, TIZ C_{max} , AUC (AUC at steady state over 1 dosing interval) and C_{min} were derived and
287 compared to simulated plasma PK parameters in human using a published physiologically-based
288 pharmacokinetic (PBPK) model (28). A dose between 50 and 100mg/kg/day BID in hamsters provided
289 C_{max} values close to that obtained in humans after a dose of 1000mg BID. A dose between 200 and
290 500mg/kg BID in hamster provided AUC values quite similar to the one obtained in humans.
291 However, human C_{min} was never reached at any dose in hamsters.

292



293

294 Figure 6: Simulated pharmacokinetic parameters of TIZ in human and hamster at steady state.

295 Predicted steady-state pharmacokinetic parameters of TIZ, i.e. C_{max} (A), AUC (B) and C_{min} (C), in human associated with
296 receiving 1000mg/day BID of NTZ (grey box) were compared with pharmacokinetic parameters of hamster receiving 50,
297 100, 200, 500 and 1000mg/kg/day BID of NTZ (colored boxes). Boxes and whiskers represent the median with inter-quartile
298 range and the 95% prediction intervals, respectively.

299

300

301 **Discussion**

302 Nitazoxanide was among the very first molecules studied at the beginning of the COVID-19
303 pandemic, revealing an *in vitro* antiviral efficacy against SARS-CoV-2 (13-19). Our study confirms
304 these results, as we found that NTZ possesses EC₅₀ under 5µM in two different cell lines. In addition,
305 we demonstrated that NTZ was active in bronchial human airway epithelia, which largely mimic the
306 structural, functional, and innate immune features of the human respiratory epithelium, albeit at
307 lower potency as compared to Remdesivir, the positive control in this assay (26).

308 It is well documented that, *in vivo*, NTZ is rapidly deacetylated to its active metabolite, TIZ (29).
309 However, only one non-peer-reviewed source reported the activity of TIZ against SARS-CoV-2
310 (<https://opendata.ncats.nih.gov/covid19/databrowser>). Here, we demonstrated that this metabolite
311 is indeed active against SARS-CoV-2 *in vitro* with an EC₅₀ of 7.48µM, reinforcing the potential use of
312 NTZ in COVID-19 management.

313 Although mainly considered as an antiprotozoal agent, NTZ, and its active circulating TIZ metabolite,
314 were identified as *in vitro* broad-spectrum antiviral compounds, since they both inhibit the
315 replication of a wide range of RNA and DNA viruses in cell culture (6, 8). Their antiviral mechanism
316 has not been clearly elucidated. However, it seems that interaction with numerous targets implicated
317 in viral pathogenesis, depending on the virus, is involved (immunomodulatory effects and direct drug
318 action) (8). Notably, post-entry inhibition by upregulation of cell's innate antiviral response, observed
319 against hepatitis C virus on cell culture (30), may be one of the efficient antiviral pathways involved in
320 SARS-CoV-2 inhibition. Recently, TMEM16 inhibitors, such as niclosamide and NTZ, have been
321 reported to protect against cell fusion induced by SARS-CoV-2 spike protein in cell culture (31). This
322 syncytia inhibition could be one of the modes of action observed *in vitro* and *ex vivo* for NTZ antiviral
323 activity against SARS-CoV-2.

324

325 Although NTZ has had only incomplete preclinical characterization, numerous clinical trials using the
326 molecule are underway around the world. We felt that the generation of robust preclinical data was
327 relevant to document the suitability of NTZ for clinical use in the treatment of COVID patients.

328 Despite promising *in vitro* results and new hypotheses on its antiviral mechanism, NTZ failed to
329 reduce the severity of SARS-CoV-2 infection *in vivo* in the Syrian hamster model. No significant
330 improvement in terms of clinical course of the disease, viral replication (based on infectious titers or
331 viral RNA yields) and/or histopathological damages in lungs was observed when using two different
332 dosing regimens of NTZ. These findings could be explained by the insufficient pulmonary diffusion of

333 TIZ, since peak concentrations in lungs (1 hour post-treatment) never exceeded its *in vitro* or *ex vivo*
334 EC₅₀. This insufficient pulmonary exposure was confirmed by the low accumulation of TIZ over time in
335 the lungs as trough concentrations after 3 days of multiple doses of NTZ were similar to those found
336 4 hours post-treatment in the single dose model. This result is in accordance with a previous clinical
337 trial assessing the safety, bactericidal activity, and pharmacokinetics of NTZ in adults with pulmonary
338 tuberculosis, where sputum concentration of NTZ was low, suggesting that it did not penetrate
339 pulmonary lesions to a sufficient degree (32). This can be explained in part by the physico-chemical
340 and pharmacokinetic characteristics of the product, which do not facilitate tissue diffusion. In
341 addition to being a moderately lipophilic molecule, TIZ is highly bound to plasma proteins (99%).
342 Therefore, the use of NTZ as a systemic treatment might be challenging.

343 The PK modeling and simulations provided further insights for the lack of NTZ efficacy in the *in vivo*
344 hamster model of SARS-CoV-2 infection. Simulations showed that the dose of 500mg/kg/day BID
345 (found ineffective in our study) was sufficient to achieve C_{max} and AUC above those observed in
346 humans at the usual dose of 1000mg/kg/day, but not sufficient to reach trough concentrations (C_{min})
347 observed in humans at this same dose. Furthermore, human C_{min} was never reached even with the
348 highest simulated dose (1000mg/kg/day BID). This prediction was confirmed in our *in vivo* study in
349 which we did not observe efficacy at the highest dose (*i.e.* 750mg/kg/day TID). The latter
350 observations show a difference in the clearance of NTZ between humans and hamsters, of which the
351 C_{min} can be considered a reflection, with a more rapid elimination in hamsters. Although differences
352 in pharmacokinetic profiles between humans and hamsters are known and widely documented,
353 these findings suggest that at the usual dose of 1000mg/kg/day in humans, NTZ will have no effect
354 on SARS-CoV-2 replication.

355

356 To potentially enhance the pulmonary diffusion and explore the possible antiviral activity of TIZ
357 within the upper respiratory tract, hamsters were treated with an intranasal NTZ emulsion
358 formulation. This alternative route of administration proved ineffective in our model, as no
359 significant improvement in any of the disease endpoints analysed was observed. As observed after
360 oral administration, TIZ trough concentration measured in lungs after 3 days of intranasal NTZ
361 administration was very low, which may also partly explain the lack of antiviral efficacy ; in all
362 samples tested, including nasal turbinates, TIZ concentration was found to be well below the *in vitro*
363 and *ex vivo* EC₅₀. This lack of TIZ accumulation in the upper respiratory tract should be interpreted
364 with caution as no active intranasal deliverable compounds was available as a positive control in our
365 study.

366

367 Overall, based on the pharmacokinetic data collected in this pre-clinical study, the use of NTZ as an
368 antiviral against SARS-CoV-2, does not seem appropriate at the current standard formulation and
369 dosage. Our results suggest that the low pulmonary bioavailability of NTZ remains the major
370 challenge that needs to be addressed in order to properly evaluate the potential antiviral effect of
371 NTZ in an animal model or in human.

372 Clinical trials with NTZ are currently ongoing and their outcome will be very useful for back-
373 translation purposes. As an example, if preliminary data of a recent trial may suggest that NTZ could
374 have some beneficial impact in preventing worsening of the disease and need for hospitalization,
375 qualitative and quantitative tests to detect SARS-CoV-2 were not significantly different between the
376 treatment arms (33). These observations corroborate our results and demonstrate that it will be
377 essential to increase the pulmonary bioavailability of NTZ in order to conclude a direct antiviral
378 impact.

379

380 In conclusion, optimization of the NTZ formulation may allow reconsideration of the potential use of
381 the drug for the treatment of SARS-CoV-2 infection. In a previous pharmacokinetic study of NTZ in
382 mice, optimal concentrations of NTZ were obtained in the lungs when the molecule was entrapped in
383 inhalable particles (34). This type of formulation combined with aerosol administration could
384 potentially lead to an effective concentration of NTZ in the animal's lungs and deserves further
385 investigation.

386 **Methods**

387

388 **Cells and human airway epithelia**

389 VeroE6 cells (ATCC CRL-1586) and Caco-2 cells (ATCC HTB-37) were cultivated under 5% CO₂ and at
390 37.5°C in minimal essential medium (MEM) supplemented with 7.5% heat-inactivated fetal bovine
391 serum (FBS), 1% non-essential amino acids and 1% Penicillin/Streptomycin (all from Life
392 Technologies).

393 Mucilair™ human airway epithelia (HAE), reconstituted from primary cells of bronchial biopsies of a
394 56-year-old donor Caucasian female with no reported pathologies, was maintained in air liquid
395 interface with specific media (all from Epithelix SARL, Geneva, Switzerland, with informed consent).

396

397 **Virus**

398 SARS-CoV-2 strain BavPat1 was provided by Pr.Christian Drosten (Berlin, Germany) through European
399 Virus Archive GLOBAL (<https://www.european-virus-archive.com/>). Inoculation with this strain at a
400 MOI of 0.001, of a 25cm² culture flask of confluent VeroE6 cells with MEM medium supplemented
401 with 2.5% FBS, allowed us to prepare virus working stocks. Each 24h the cell supernatant medium
402 was replaced in order to be harvested at the peak of infection. It was supplemented with 25mM
403 HEPES (Sigma-Aldrich), aliquoted and stored at -80°C. Experiments with infectious virus were
404 performed in a biosafety level 3 laboratory.

405

406 ***In vitro* determination of EC₅₀ and CC₅₀**

407 One day prior to infection, 96-well culture plates were seeded with 5×10^4 VeroE6 or Caco-2 cells in
408 100 μ L assay medium per well (containing 2.5% FCS). The next day, eight 2-fold serial dilutions of
409 compounds (from 20 μ M to 0.16 μ M for NTZ (BLDpharm) and from 100 μ M to 0.78 μ M for TIZ
410 (MedChemExpress)) in triplicate were added to the cells (25 μ L/well, in assay medium). For the
411 determination of the 50% and 90% effective concentrations (EC₅₀, EC₉₀; compound concentration
412 required to inhibit by 50% or 90% viral RNA replication), four “virus control” wells were
413 supplemented with 25 μ L of assay medium without any compounds. After 15min, a preset amount of
414 virus diluted in 25 μ L of assay medium was added to the wells. This quantity of virus was calibrated so
415 that the viral replication was still in the exponential growth phase for the readout, as previously
416 described (24, 25, 35). Four “cell control” wells were supplemented with 50 μ L of assay medium
417 without any compounds or virus. On each culture plate, a positive control compound (Remdesivir,
418 BLDpharm) was added in duplicate with eight 2-fold serial dilutions (0.16 μ M to 20 μ M). Plates were
419 incubated for 2 days at 37°C prior to quantification of the viral genome by real-time RT-PCR as
420 described below. For the determination of the 50% cytotoxic concentrations (CC₅₀; compound
421 concentration required to reduce by 50% cell viability), the same culture conditions were used,
422 without addition of the virus, and cell viability was measured using CellTiter Blue® (Promega)
423 following manufacturer’s instructions. EC₅₀, EC₉₀ and CC₅₀ were determined using logarithmic
424 interpolation as previously described (25). The selectivity index of the compounds was calculated as
425 the ratio of the CC₅₀ over the EC₅₀.

426

427 ***Ex vivo* determination of antiviral activity**

428 After being washed with pre-warmed OptiMEM medium (Life technologies), human airway epithelia
429 were infected with SARS-CoV-2 at the apical side using a MOI of 0.1, as previously described
430 (Pizzorno et al., 2020). Cells were cultivated in a basolateral medium that contained NTZ or
431 remdesivir (positive control) at different concentrations or with no drug (virus control). Each day,
432 medium was renewed and samples containing viral RNA were collected by washing the apical side
433 with 200 μ L of pre-warmed OptiMEM medium. Four day after the infection, total intracellular RNA of
434 each well was extracted using the RNeasy 96 HT kit (Qiagen) following manufacturer’s instructions.
435 Viral RNA was quantified by RT-qPCR and infectious titers were determined in daily samples by
436 TCID₅₀, both described below. *Ex vivo* experiments were approved by ethical committee and were
437 conducted according to the declaration of Helsinki on biomedical research (Hong Kong amendment,
438 1989).

439

440 ***In vivo* experiments**

441 Approval and authorization

442 *In vivo* experiments were approved by the local ethical committee (C2EA—14) and the French
443 ‘Ministère de l’Enseignement Supérieur, de la Recherche et de l’Innovation’ (APAFIS#23975). Animal
444 experimentations were performed in accordance with the French national guidelines and the
445 European legislation covering the use of animals for scientific purposes.

446 Animal handling

447 Three-week-old female Syrian hamsters were provided by Janvier Labs. Animals were maintained in
448 ISOcage P - Bioexclusion System (Techniplast) with unlimited access to water/food and 14h/10h
449 light/dark cycle. Animals were weighed and monitored daily for the duration of the study to detect
450 the appearance of any clinical signs of illness/suffering. General anesthesia was obtained with
451 isoflurane (Isoflurin®, Axience). Euthanasia, which was also realized under general anesthesia, was
452 performed by cervical dislocation.

453 Hamster Infection

454 Four-week-old anesthetized animals were intranasally infected with 50µL containing 10⁴ TCID₅₀ of
455 virus in 0.9% sodium chloride solution. The mock-infected group was intranasally inoculated with
456 50µL of 0.9% sodium chloride solution.

457 Drug preparation and administration

458 Hamsters were orally treated with either a NTZ solution at 10mg/mL, suspension at 27mg/mL or
459 emulsion at 2.5mg/mL, prepared from NTZ powder (BLD Pharm). The solution was prepared with
460 0.5% of hydroxypropyl methylcellulose and 0.1% of tween 80. For the suspension NTZ was dissolved
461 in a vehicle composed of 90% (v / v) sterile distilled water, 7% (v / v) of tween 80 and 3% (v / v)
462 ethanol 80%. The emulsion (aqueous/organic phase ratio of 80/20) for intranasal instillation was
463 prepared with an aqueous phase (sterile distilled water 94% and absolute ethanol 6%) added
464 gradually to an organic phase (NTZ 20mg/mL in cinnamaldehyde 75% and Kolliphore EL 25%) under
465 constant stirring. A solution of favipiravir, reconstituted from anhydrous favipiravir (Toyama-
466 Chemical) with 0.9% sodium chloride solution, was used for intra-peritoneally and intranasally
467 treatment. Control group were orally or intranasally inoculated with a 0.9% sodium chloride solution.

468 Tissue collection

469 Lungs, nasal turbinates and blood were collected immediately after euthanasia. The left pulmonary
470 lobe was first rinsed in 10mL of 0.9% sodium chloride solution, blotted with filter paper and weighed.
471 Nasal turbinates and pulmonary lobes were transferred to a 2mL tube containing respectively 500µL
472 or 1mL of 0.9% sodium chloride solution and 1mm or 3mm glass beads. They were crushed using a

473 Tissue Lyser machine (Retsch MM400) for 5min at 30 cycles/s and then centrifuged 10min at
474 16,200g. Crushed nasal turbinates were stored at -80°C while lung supernatant media were
475 transferred to a 1.5mL tube, for another centrifugation during 10 min at 16,200g prior being stored
476 at -80°C. One milliliter of blood was harvested in a 2mL tube containing 100µL of 0.5M EDTA (Life
477 Technologies). Blood was centrifuged for 10 min at 16,200g and stored at -80°C.

478

479 **Quantitative real-time RT-PCR (RT-qPCR) assays**

480 All experiments were conducted in a molecular biology laboratory that is specifically devoted to
481 molecular clinical diagnosis and which includes separate laboratories dedicated to each step of the
482 procedure. Prior to PCR amplification, RNA extraction was carried out using the QIAamp 96 DNA kit
483 and the Qiacube HT kit and the Qiacube HT (both from Qiagen) following the manufacturer's
484 instructions. Shortly, 100µl of tissue clarified homogenates, spiked with 10µL of internal control
485 (bacteriophage MS2), or viral supernatant were transferred into an S-block containing the
486 recommended volumes of VXL, proteinase K and RNA carrier.

487 RT-qPCR (SARS-CoV-2 and MS2 viral genome detection) were performed with the GoTaq 1-step qRt-
488 PCR kit (Promega) using 3.8µL of extracted RNA and 6.2µL of RT-qPCR mix that contains 250nM of
489 each primer and 75nM of probe. Primers and probes sequences used are described in Supplementary
490 Table 3. Quantification was provided by four 2 log serial dilutions of an appropriate T7-generated
491 synthetic RNA standard of known quantities (10^2 to 10^8 copies/reaction). Amplification was
492 performed with the QuantStudio 12K Flex Real-Time PCR System (Applied Biosystems) using standard
493 fast cycling parameters: 10min at 50°C, 2 min at 95°C, and 40 amplification cycles (95°C for 3 sec
494 followed by 30sec at 60°C). qPCR (β -actine gene detection) was performed under the same condition
495 as RT-qPCR with the following modifications: we used the Express one step qPCR Universal kit
496 (ThermoFisher Scientific) and the 50°C step of the amplification cycle was removed. Results were
497 analyzed using QuantStudio 12K Flex Applied Biosystems software v1.2.3.

498

499 **Tissue-culture infectious dose 50 (TCID₅₀) assay**

500 To determine infectious titers, 96-well culture plates containing confluent VeroE6 cells were
501 inoculated with 150µL per well of serial dilutions of each sample (ten-fold or four-fold dilutions when
502 analyzing cell supernatant media or lung clarified homogenates respectively). Each dilution was
503 performed in sextuplicate. After 5 days of incubation, plates were read for the absence or presence
504 of cytopathic effect in each well. Infectious titers were estimated using the method characterized by
505 Reed & Muench (36).

506

507 **Nitazoxanide quantification in plasma and tissues**

508 Quantification of TIZ in plasma and lung tissues was performed by high-performance liquid
509 chromatography with UV detection method (Alliance 2695, Waters, USA) with a lower limit of
510 quantification of 0.01 μ g/mL. The mobile phase consisted of 0.1% FA in water and 0.1% of FA in ACN
511 (65:35, v/v). The chromatographic separation was achieved using an isocratic mode with an Xbridge
512 BEH C18 2.5 μ m 4.6 \times 100mm column. Peak area was quantified at 340nm using the Waters 2489
513 detector. TIZ was extracted by a simple protein precipitation method, using acetonitrile for plasma
514 and ice-cold acetonitrile for clarified lung homogenates. Briefly, 200 μ L of samples matrix was added
515 to 1000 μ L of acetonitrile solution containing the internal standard (thiopental), then vortexed for
516 2min followed by centrifugation for 10min at 4°C. The supernatant medium was evaporated under
517 vacuum, then transferred to a 1.5mL Eppendorf tube. The dried residue was reconstituted with 100 μ L
518 of ACN:water (50:50), vortexed for 30 seconds and centrifuged again for 10min at 4°C. The
519 supernatant was transferred to an autosampler and 50 μ L was injected.

520

521 **Histology**

522 Animal handling, hamster infections, NTZ preparation and oral administrations were performed as
523 described above. The anatomo-histological study was implemented as previously described (22).
524 Briefly, lungs were collected after intratracheal instillation of 4% (w/v) formaldehyde solution, and
525 then fixed 72h at room temperature with a 4% (w/v) formaldehyde solution before being embedded
526 in paraffin. Tissue sections of 3.5 μ m were stained with hematoxylin-eosin (H&E) and blindly analyzed
527 by a certified veterinary pathologist. Microscopic examination was done using a Nikon Eclipse E400
528 microscope. Different anatomic compartments were examined (1) for bronchial and alveolar walls, a
529 score of 0 to 4 was assigned based on severity of inflammation; (2) regarding alveoli, a score of 0 to 2
530 was assigned based on presence and severity of hemorrhagic necrosis; (3) regarding vessel changes
531 (leucocytic accumulation in vascular wall or in endothelial compartment), absence or presence was
532 scored 0 or 1 respectively. A cumulative score was then calculated and assigned to a grade of severity
533 (see Supplementary Table 4).

534

535 **Pharmacokinetic modelling and simulation**

536 NTZ is rapidly and completely hydrolyzed into its active metabolite TIZ (29, 37). Therefore, the
537 pharmacokinetic properties of NTZ were described using measured TIZ concentration in plasma.
538 At each time point, approximate 80 μ L of blood were collected from the submandibular vein or the
539 saphenous vein of hamsters. All samples were transferred into commercial K2-EDTA tubes, placed on

540 ice until processed for plasma extraction by centrifugation and stored at -70°C before analysis. A LC-
541 MS/MS-AI Triple Quad 5500 was used to determine TIZ concentrations. The mobile phase was a
542 gradient of 0.1% formic acid (FA) in water and 0.1% of FA in acetonitrile (ACN), the column was an
543 ACQUITY UPLC HSS T3 1.8µm 2.1 × 50mm. For mass spectrometry a positive electrospray ionization
544 was used, and a selected reaction monitoring was set to select TIZ: [M+H]⁺m/z: 266.0 / 121.2 and
545 dexamethasone: [M+H]⁺m/z: 393.0 / 373.1 as internal standard.

546 Pharmacokinetic profiles of TIZ in hamster were analyzed using a nonlinear mixed-effects modelling
547 approach. The population pharmacokinetics analysis was performed using NONMEM® version 7.4.
548 The final pharmacokinetic model was established by evaluating one-, two-, and three-compartment
549 disposition models, as well as several different absorption models (i.e. first-order absorption, first-
550 order absorption with lag time, and transit absorption models). The inter-individual variabilities of
551 pharmacokinetic parameters were implemented as a log-normal distribution and the residual
552 unexplained variability was modelled as an exponential error. Different doses of NTZ (i.e., 50, 100,
553 200, 500 and 1000mg/kg/day BID) were used to simulate TIZ exposures in hamsters (n=100) in order
554 to compare to the simulated human exposure.

555 To simulate human PK profiles, a one-compartment model was used with pharmacokinetic
556 parameters from an established PBPK model (28), developed to describe pharmacokinetic data of TIZ
557 plasma concentrations in healthy individuals receiving single doses of 500-4000mg NTZ with/without
558 food, presenting an apparent clearance of 19.34L/h and a volume of distribution of 38.68 L. The
559 absorption was described with a first-order process and the rate constant (k_a) of 0.45h⁻¹ was
560 assumed in order to generate the mean concentration-time profile with a T_{max} at approximately 2
561 hours, as reported in healthy volunteers (38). This model was used to simulate drug exposure at
562 steady state in human after a dosing regimen of 1000mg/day BID of NTZ, administered to 100
563 individuals. A total of 10 doses (5 days) were used for estimating the convergence rate to steady
564 state.

565 All exposure simulations were performed in R version 4.0.4 using the mlxR package (39).

566

567 **Graphical representations and statistical analysis**

568 Graphical representations and statistical analyses (two-sided tests when relevant) were performed
569 with Graphpad Prism 7 (Graphpad software). P-values lower than 0.05 were considered statistically
570 significant. Statistical details for each experiment are described in the figure legends and in
571 corresponding Supplementary Data. Experimental timelines were created on biorender.com.

572

573 **Acknowledgments**


574 We thank Laurence Thirion (UVE; Marseille) for providing RT-qPCR systems. We thank Camille Placidi
575 (UVE; Marseille) for her technical contribution. We thank Pr Drosten and Pr Drexler for providing the
576 SARS-CoV-2 strain through the European Research infrastructure EVA GLOBAL. We thank Toyama-
577 Chemical Favipiravir for kindly providing the favipiravir. This work was supported by the Fondation de
578 France “call FLASH COVID-19”, project TAMAC, by “Institut national de la santé et de la recherche
579 médicale” through the REACTing (REsearch and ACTion targeting emerging infectious diseases), by
580 REACTING/ANRS MIE under the agreement No. 21180 (‘Activité des molécules antivirales dans le
581 modèle hamster’), by European Virus Archive Global (EVA 213 GLOBAL) funded by the European
582 Union’s Horizon 2020 research and innovation program under grant agreement No. 871029 and
583 DNDi under support by the Wellcome Trust Grant ref: 222489/Z/21/Z through the COVID-19
584 Therapeutics Accelerator”. Part of this work was supported by the Wellcome Trust [220211]. Part of
585 the work was done on the Aix Marseille University antivirals platform “AD2P”. For the purpose of
586 open access, the author has applied a CC BY public copyright licence to any Author Accepted
587 Manuscript version arising from this submission.
588

589 **Materials & Correspondence**

590 Correspondence to Jean-Sélim Driouich.

591 **Supplementary Data**


592



593

594 Supplementary Fig. 1: Clinical course of the disease (n=4 animals/group). Normalized weight at day n was calculated as


595 follows: % of initial weight of the animal at day n. Data represent mean \pm SD (Details in Supplementary Data 3).



596

597 Supplementary Fig. 2: Antiviral activity of intranasal treatment of NTZ in a hamster model.


598 Groups of 6 hamsters were intranasally infected with 10^4 TCID₅₀ of virus. **a** Experimental timeline. **b** Viral replication in lung
 599 based on infectious titers (measured using a TCID₅₀ assay) expressed in TCID₅₀/g of lung (n=6 animals/group). **c** Viral
 600 replication in lung based on viral RNA yields (measured using an RT-qPCR assay) expressed in viral genome copies/g of lung
 601 (n=6 animals/group). **d** Plasma viral loads (measured using an RT-qPCR assay) are expressed in viral genome copies/mL of
 602 plasma (the dotted line indicates the detection threshold of the assay) (n=6 animals/group). **e** Viral replication in nasal
 603 turbinates based on infectious titers (measured using a TCID₅₀ assay) expressed in TCID₅₀/copy of β -actin gene (n=6
 604 animals/group). **f** Viral replication in nasal turbinates based on viral RNA yields (measured using an RT-qPCR assay)
 605 expressed in viral genome copies/copy of β -actin gene (n=6 animals/group). **g** Clinical course of the disease (n=6
 606 animals/group). Normalized weight at day n was calculated as follows: % of initial weight of the animal at day n. Data
 607 represent mean \pm SD (Details in Supplementary Data 1). ** symbols indicate that the average value for the group is
 608 significantly lower than that of the untreated group with a p-value ranging between 0.001-0.01 (Details in Supplementary
 609 Data 1).



610

611 Supplementary Fig. 3: Plasma concentration of TIZ following administration of NTZ to hamsters at doses of 485mg/kg (■),

612 98.1mg/kg (○) and 25.5mg/kg. Three animals per dose group were included error bars represent the standard deviation.



613

614 Supplementary Fig. 4: Goodness-of-fit diagnostics of final nitazoxanide population pharmacokinetic model in hamster. (A)
615 Observed tizoxanide concentrations vs population predictions, (B) observed tizoxanide concentrations vs individually
616 predicted concentrations, (C) conditionally weighted residual vs time, and (D) conditionally weighted residual vs population
617 predictions. The open circles represent the observed tizoxanide concentrations. The solid black lines represent the line of
618 identity and the dashed red lines represent a local polynomial regression fitting of all observations (i.e. trend line).

	Time post-treatment	Plasma ($\mu\text{g}/\text{mL}$)	Lung ($\mu\text{g}/\text{g}$)	L/p ratio	Nasal turbinates ($\mu\text{g}/\text{mL}$)
Multiple Dose : 2.8mg/kg/day TID (at 3 dpi)	12 hours	0.01 £ (0.03 μM)	0.10 ; 0.11 \$ (0.39 ; 0.41 $\mu\text{M}/\text{g}$)	1279.5	0.01 £ (0.06 μM)

619

620 Supplementary Table 1: Plasma lung and nasal turbinates concentrations of TIZ after administration of multiple dose of NTZ.
621 PK realized after 3 days of nitazoxanide administered three times a day, at the end of the dosing interval (trough
622 concentrations). Data represent individual values (Details in Supplementary Data 4). Symbols \$ and £ represent respectively
623 4 or 5 values below the limit of quantification.

Parameter	Population estimates ^a (%RSE) ^b	95%CI ^b	IIV ^a [%CV] (%RSE) ^b	95%CI ^b
F	1 (fixed)	-	-	-
CL/F (L/h)	0.651 (11.9)	0.504-0.866	40.9 (26.5)	14.8-53.5
V/F (L)	0.128 (48.3)	0.044-0.359	-	-
Q/F (L/h)	0.391 (73.5)	0.134-1.373	55.7 (156)	26.8-220
VP/F (L)	0.262 (32.5)	0.120-0.426	-	-
k _a (h ⁻¹)	1.74 (56.2)	0.941-5.945	99.6 (33.4)	40.8-267
σ	0.151	0.088-0.204	-	-

624

625

626

Supplementary Table 2: Population pharmacokinetic parameters from the final model of NTZ in hamster.

627

^a Population mean values, inter-individual variability (IIV) were estimated by NONMEM. The coefficient of

variation (%CV) for IIV were calculated as $100 \times \sqrt{\exp(\text{estimate}) - 1}$.

628

^b Relative standard error (%RSE) was calculated as $100 \times \left(\frac{SD}{\text{Mean value}} \right)$ from the non-parametric bootstrap results (n=1,000).

629

The 95% confidence interval (95%CI) is presented as the 2.5 to 97.5 percentiles of bootstrap estimates.

630

(F : bioavailability ; CL/F : oral clearance ; V/F : volume of distribution of the central compartment ; Q/F :

631

intercompartmental clearance ; VP/F : volume of distribution of peripheral compartment ; K_a : absorption rate constant ; σ

632

: residual variability)

Gene Target	Primer and probes sequences	Amplicon length	Reference
Sars-CoV-2 RNA-dependent RNA polymerase	Fwd: 5'-GTGARATGGTCATGTGTGGCGG-3' Rev: 5'-CARATGTTAAASACACTATTAGCATA-3' Probe: 5'-FAM-CAGGTGGAACCTCATCAGGAGATGC-TAMRA-3'	99pb	Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR (Corman et al.)
Syrian hamster γ -actin	Fwd: 5'-ACAGAGAGAAGATGACGCAGATAATG-3' Rev: 5'-GCCTGAATGGCCACGTACA-3' Probe: 5'-FAM-TTGAAACCTTCAACACCCAGCC-TAMRA-3'	70pb	Duplex real-time reverse transcriptase PCR to determine cytokine mRNA expression in a hamster model of New World cutaneous leishmaniasis (Espitita et al.)
Bacteriophage MS2	Fwd: 5'-CTCTGAGAGCGGCTCTATTGGT-3' Rev: 5'-GTTCCCTACAACGAGCCTAAATTC-3' Probe: 5'-VIC-TCAGACACGCGGTCCGCTATAACGA-TAMRA-3'	100pb	RNA and DNA Bacteriophages as Molecular Diagnosis Controls in Clinical Virology: A Comprehensive Study of More than 45,000 Routine PCR Tests (Ninove et al.)

633

634 Supplementary Table 3: (RT)-qPCR systems.

Lesion	Description	Intensity	Score
Interstitial pneumonia	1 or 2 foci with 10-20 cells or small area with two-fold thickening of alveolar septa	Mild	1
	3 to 5 foci with 10-30 cells or widespread areas with two-fold thickening of alveolar septa	Moderate	2
	5 foci of 10-50 cells or widespread areas with two-fold or three-fold thickening of alveolar septa throughout the lung	Marked	3
	5 foci of 10-100 cells or widespread areas with three to fourfold-thickened alveolar septa throughout the lung	Severe	4
Bronchitis	1 or 2 bronchi section(s) filled with rare necrotic/inflammatory cells or partially surrounded by scarce inflammatory cells	Mild	1
	3 to 5 bronchi filled with necrotic/inflammatory cells or partially surrounded by a few inflammatory cells	Moderate	2
	6 to 10 bronchi filled with necrotic/inflammatory cells, partially or sub-completely surrounded by inflammatory cells	Marked	3
	Numerous bronchi filled with inflammatory or cellular debris or completely surrounded by numerous inflammatory cells	Severe	4
Endothelitis, vasculitis	Absent	-	0
	Present	-	1
Hemorrhagic necrosis	Absent	-	0
	Focal to multifocal	Mild to moderate	1
	Coalescing to extensive necrosis	Severe	2

635

636

Supplementary Table 4: Histopathological semi-quantitative lung inflammation scoring system

Cumulative score	Grade	Bronchointerstitial pneumonia
0	0	Normal
1-3	1	Mild
4-5	2	Moderate
6-8	3	Marked
9-10	4	Severe

637

638 Supplementary Table 5: Histopathological lung inflammation semi-quantitative grading

639 References

640

- 641 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with
642 Pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-33.
- 643 2. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated
644 with a new coronavirus of probable bat origin. *Nature*. 2020;579(7798):270-3.
- 645 3. WHO. World Health Organization. WHO Director-General's opening remarks at the media
646 briefing on COVID-19 - 11 March 2020 2020 [Available from: [https://www.who.int/director-
647 general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-
648 19--11-march-2020](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19--11-march-2020).
- 649 4. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-specific T
650 cell immunity in cases of COVID-19 and SARS, and uninfected controls. *Nature*. 2020;584(7821):457-
651 62.
- 652 5. Kratky M, Vinsova J. Antiviral activity of substituted salicylanilides--a review. *Mini Rev Med
653 Chem*. 2011;11(11):956-67.
- 654 6. Rossignol JF. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. *Antiviral Res*.
655 2014;110:94-103.
- 656 7. Cao J, Forrest JC, Zhang X. A screen of the NIH Clinical Collection small molecule library
657 identifies potential anti-coronavirus drugs. *Antiviral Res*. 2015;114:1-10.
- 658 8. Stachulski AV, Taujanskas J, Pate SL, Rajoli RKR, Aljayyousi G, Pennington SH, et al.
659 Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?
660 *ACS Infect Dis*. 2021;7(6):1317-31.
- 661 9. Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, et al. Advances in respiratory
662 virus therapeutics - A meeting report from the 6th isrv Antiviral Group conference. *Antiviral Res*.
663 2019;167:45-67.
- 664 10. Rossignol JF. Nitazoxanide, a new drug candidate for the treatment of Middle East
665 respiratory syndrome coronavirus. *J Infect Public Heal*. 2016;9(3):227-30.
- 666 11. Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG. Thiazolidines, a New Class of Anti-
667 influenza Molecules Targeting Viral Hemagglutinin at the Post-translational Level. *Journal of
668 Biological Chemistry*. 2009;284(43):29798-808.
- 669 12. Belardo G, Cenciarelli O, La Frazia S, Rossignol JF, Santoro MG. Synergistic effect of
670 nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro. *Antimicrob Agents
671 Chemother*. 2015;59(2):1061-9.
- 672 13. Martins PR, Barreto-Alves JA, Fakhouri R. Potential role for nitazoxanide in treating SARS-
673 CoV-2 infection. *Am J Physiol-Lung C*. 2020;319(1):L35-L6.
- 674 14. Chibber P, Haq SA, Ahmed I, Andrabi NI, Singh G. Advances in the possible treatment of
675 COVID-19: A review. *Eur J Pharmacol*. 2020;883.
- 676 15. Alonso DF, Farina HG. Repurposing of host-based therapeutic agents for the treatment of
677 coronavirus disease 2019 (COVID-19): a link between antiviral and anticancer mechanisms? *Int J
678 Antimicrob Agents*. 2020;56(3):106125.
- 679 16. Dos Santos WG. Natural history of COVID-19 and current knowledge on treatment
680 therapeutic options. *Biomed Pharmacother*. 2020;129:110493.
- 681 17. Yang CW, Peng TT, Hsu HY, Lee YZ, Wu SH, Lin WH, et al. Repurposing old drugs as antiviral
682 agents for coronaviruses. *Biomed J*. 2020;43(4):368-74.
- 683 18. Arshad U, Pertinez H, Box H, Tatham L, Rajoli RK, Curley P, et al. Prioritisation of potential
684 anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and
685 target site concentrations derived from their established human pharmacokinetics. *medRxiv*.
686 2020:2020.04.16.20068379.
- 687 19. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively
688 inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res*. 2020;30(3):269-71.

- 689 20. Lokhande AS, Devarajan PV. A review on possible mechanistic insights of Nitazoxanide for
690 repurposing in COVID-19. *Eur J Pharmacol*. 2021;891:173748.
- 691 21. Braga L, Ali H, Secco I, Chiavacci E, Neves G, Goldhill D, et al. Drugs that inhibit TMEM16
692 proteins block SARS-CoV-2 spike-induced syncytia. *Nature*. 2021;594(7861):88-93.
- 693 22. Driouich J-S, Cochin M, Lingas G, Moureau G, Touret F, Petit PR, et al. Favipiravir antiviral
694 efficacy against SARS-CoV-2 in a hamster model. *bioRxiv*. 2020:2020.07.07.191775.
- 695 23. Touret F, Driouich J-S, Cochin M, Rémi Petit P, Gilles M, Barthélémy K, et al. Preclinical
696 evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2. *bioRxiv*.
697 2020:2020.11.17.386904.
- 698 24. Touret F, Gilles M, Barral K, Nougairede A, van Helden J, Decroly E, et al. In vitro screening of
699 a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. *Sci Rep*.
700 2020;10(1):13093.
- 701 25. Touret F, Baronti C, Goethals O, Van Loock M, de Lamballerie X, Querat G. Phylogenetically
702 based establishment of a dengue virus panel, representing all available genotypes, as a tool in
703 dengue drug discovery. *Antiviral Res*. 2019;168:109-13.
- 704 26. Pizzorno A, Padey B, Julien T, Trouillet-Assant S, Traversier A, Errazuriz-Cerda E, et al.
705 Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia. *Cell*
706 *Rep Med*. 2020;1(4):100059.
- 707 27. Chan JF, Zhang AJ, Yuan S, Poon VK, Chan CC, Lee AC, et al. Simulation of the Clinical and
708 Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster
709 Model: Implications for Disease Pathogenesis and Transmissibility. *Clin Infect Dis*. 2020;71(9):2428-
710 46.
- 711 28. Rajoli RKR, Pertinez H, Arshad U, Box H, Tatham L, Curley P, et al. Dose prediction for
712 repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. *Br J Clin Pharmacol*.
713 2021;87(4):2078-88.
- 714 29. Broekhuysen J, Stockis A, Lins RL, De Graeve J, Rossignol JF. Nitazoxanide: pharmacokinetics
715 and metabolism in man. *Int J Clin Pharmacol Ther*. 2000;38(8):387-94.
- 716 30. Elazar M, Liu M, McKenna SA, Liu P, Gehrig EA, Puglisi JD, et al. The anti-hepatitis C agent
717 nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase
718 activated by double-stranded RNA activation. *Gastroenterology*. 2009;137(5):1827-35.
- 719 31. Braga L, Ali H, Secco I, Chiavacci E, Neves G, Goldhill D, et al. Drugs that inhibit TMEM16
720 proteins block SARS-CoV-2 spike-induced syncytia. *Nature*. 2021.
- 721 32. Walsh KF, McAulay K, Lee MH, Vilbrun SC, Mathurin L, Jean Francois D, et al. Early
722 Bactericidal Activity Trial of Nitazoxanide for Pulmonary Tuberculosis. *Antimicrob Agents Chemother*.
723 2020;64(5).
- 724 33. Rossignol J-F, Matthew CB, Oaks JB, Bostick BG, Vora KN, Fulgencio J, et al. Early treatment
725 with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent
726 hospitalization. *medRxiv*. 2021:2021.04.19.21255441.
- 727 34. Gupta A, Tulsankar SL, Bhatta RS, Misra A. Pharmacokinetics, Metabolism, and Partial
728 Biodistribution of "Pincer Therapeutic" Nitazoxanide in Mice following Pulmonary Delivery of
729 Inhalable Particles. *Mol Pharm*. 2017;14(4):1204-11.
- 730 35. Delang L, Li C, Tas A, Querat G, Albuлесcu IC, De Burghgraeve T, et al. The viral capping
731 enzyme nsP1: a novel target for the inhibition of chikungunya virus infection. *Sci Rep-Uk*. 2016;6.
- 732 36. Reed LJaMH. A simple method of estimating fifty per cent endpoint. *American Journal of*
733 *Epidemiology*. 1938;27 (3):493-7.
- 734 37. Harausz EP, Chervenak KA, Good CE, Jacobs MR, Wallis RS, Sanchez-Felix M, et al. Activity of
735 nitazoxanide and tizoxanide against *Mycobacterium tuberculosis* in vitro and in whole blood culture.
736 *Tuberculosis (Edinb)*. 2016;98:92-6.
- 737 38. Balderas-Acta JI, Ríos-Rodríguez Bueno EP, Pérez-Becerril F, Espinosa-Martínez C, Burke-Fraga
738 V, González-de la Parra G. Bioavailability of Two Oral-Suspension Formulations of a Single Dose of
739 Nitazoxanide 500 mg: An Open-Label, Randomized-Sequence, Two-Period Crossover, Comparison in
740 Healthy Fasted Mexican Adult Volunteers. *J Bioequiv Availab*. 2011;3(3):043-7.

741 39. Lavielle M. mlxR: Simulation of Longitudinal Data. 2017.
742